Big Cypress Acquisition Corp. Merger Partner SAB Biotherapeutics Announces Independent Data Safety Monitoring Board Has Completed Interim Analysis Of SAB-185 In Phase 2 Portion Of ACTIV-2 Trial And Recommended Advancement To Phase 3